Chemoimmunotherapy: reengineering tumor immunity.
Chemoimmunotherapy: reengineering tumor immunity.
复制标题
DOI：
10.1007/s00262-012-1388-0
复制
发表时间：
2013-02
影响因子：
5.8
通讯作者：
Emens, Leisha A.
中科院分区：
文献类型：
--
作者：
Chen, Gang;Emens, Leisha A.
癌症化疗药物长期以来被认为是免疫抑制剂。然而，最近的数据表明，当以标准剂量和时间表给予时，一些细胞毒性药物部分地通过促进对肿瘤的免疫应答来有效治疗癌症。这些药物诱导一种具有免疫活性的肿瘤细胞死亡形式，从而诱导对肿瘤特异性的适应性免疫应答。此外，癌症化疗药物可以通过对肿瘤微环境中存在的恶性和正常宿主细胞的辅助和很大程度上未被认识到的免疫作用来促进肿瘤免疫。这些更微妙的免疫调节作用取决于药物本身、剂量及其与免疫干预相关的时间表。最近批准的两种针对前列腺癌和黑色素瘤的新免疫疗法预示着癌症治疗的新时代，并引起了人们对免疫疗法作为癌症治疗有效方法的兴趣。详细了解化疗药物与免疫系统之间相互作用的细胞和分子基础，对于设计将新的基于免疫的疗法整合到各种癌症的护理标准中的最佳策略至关重要，从而为癌症患者带来最大的长期临床益处。
Cancer chemotherapy drugs have long been considered immune suppressive. However, more recent data indicate that some cytotoxic drugs effectively treat cancer in part by facilitating an immune response to the tumor when given at the standard dose and schedule. These drugs induce a form of tumor cell death that is immunologically active, thereby inducing an adaptive immune response specific for the tumor. In addition, cancer chemotherapy drugs can promote tumor immunity through ancillary and largely unappreciated immunologic effects on both the malignant and normal host cells present within the tumor microenvironment. These more subtle immunomodulatory effects are dependent on the drug itself, its dose, and its schedule in relation to an immune-based intervention. The recent approvals of two new immune-based therapies for prostate cancer and melanoma herald a new era in cancer treatment and have led to heightened interest in immunotherapy as a valid approach to cancer treatment. A detailed understanding of the cellular and molecular basis of interactions between chemotherapy drugs and the immune system is essential for devising the optimal strategy for integrating new immune-based therapies into the standard of care for various cancers, resulting in the greatest long-term clinical benefit for cancer patients.
登录
查看更多内容
影响因子：
7.4
作者：
Brignone C;Gutierrez M;Mefti F;Brain E;Jarcau R;Cvitkovic F;Bousetta N;Medioni J;Gligorov J;Grygar C;Marcu M;Triebel F
通讯作者：
Triebel F
影响因子：
11.5
作者：
Arlen, PM;Gulley, JL;Dahut, W
通讯作者：
Dahut, W
DOI：
10.1084/jem.20050915
发表时间：
2005-12-19
期刊：
The Journal of experimental medicine
影响因子：
--
作者：
Casares N;Pequignot MO;Tesniere A;Ghiringhelli F;Roux S;Chaput N;Schmitt E;Hamai A;Hervas-Stubbs S;Obeid M;Coutant F;Métivier D;Pichard E;Aucouturier P;Pierron G;Garrido C;Zitvogel L;Kroemer G
通讯作者：
Kroemer G
影响因子：
5.8
作者：
Adair, Sara J.;Hogan, Kevin T.
通讯作者：
Hogan, Kevin T.
影响因子：
5.8
作者：
Banissi, Claire;Ghiringhelli, Francois;Carpentier, Antoine F.
通讯作者：
Carpentier, Antoine F.